glp-1 drug List of approved and pending medications As GLP-1 drugs go mainstream,

Chronic daily administration of cotadutide over 27 days in obese mice was associated with food intake reduction, decreased adiposity, improved fasting glucose, and increased energy expenditure

[33] [34] In 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance on GLP-1 medication after an increase in reports to the agency's Yellow Card Scheme of acute pancreatitis, with fatalities, in patients taking semaglutide or tirzepatide, to warn of a small risk of developing severe acute pancreatitis

(ii) the insufficient power to detect any association

In the study, there was a statistically significant 24% relative risk reduction in the combined endpoint of kidney disease worsening, kidney failure, and death due to cardiovascular disease compared to placebo after three years, when added to standard of care

What is the FDA-approved use of Ozempic

Shin S, Le Lay J, Everett LJ, Gupta R, Rafiq K, Kaestner KH